Ribogenyx

Ribogenyx is a biotechnology company developing small-molecule therapies to improve protein synthesis accuracy in ageing cells.

Its approach targets translational fidelity, the accuracy with which ribosomes translate messenger RNA into proteins. By reducing production errors, the company aims to preserve protein quality and cellular resilience.

Potential applications include neurodegenerative diseases, fibrosis and age-related muscle decline. Its technology is at an early research stage, with clinical effectiveness yet to be established.